Interim report
Page 1
Note: This document has been translated from the Japanese-language original (hereinafter, the "original") for reference purposes only. In the event of any discrepancy between this translated document and the original, the original shall prevail. The original of Quarterly Consolidated Financial Statements has undergone a review by the Company's audit firm. Please refer to the Japanese review report for details. August 4, 2026 SSSSSuuuuummmmmmmmmmaaaaarrrrryyyyy ooooofffff CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd FFFFFiiiiinnnnnaaaaannnnnccccciiiiiaaaaalllll RRRRReeeeesssssuuuuullllltttttsssss fffffooooorrrrr FFFFFiiiiirrrrrsssssttttt QQQQQuuuuuaaaaarrrrrttttteeeeerrrrr FFFFFiiiiissssscccccaaaaalllll YYYYYeeeeeaaaaarrrrr 22222000002222266666 (((((UUUUUnnnnndddddeeeeerrrrr IIIIIFFFFFRRRRRSSSSS))))) Company name: Sumitomo Chemical Co., Ltd. Listing: Tokyo Stock Exchange Securities code: 4005 URL: https://www.sumitomo-chem.co.jp/english/ Representative: Nobuaki Mito, Representative Director & President Inquiries: Shoko Wato, General Manager, Corporate Communications Dept. Telephone: +81-3-5201-0200 Scheduled date to commence dividend payments: － Preparation of supplementary material on financial results: Yes Holding of financial results briefing: Yes (for institutional investors and analysts) (All amounts are rounded to the nearest million yen.) 11111..... CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd FFFFFiiiiinnnnnaaaaannnnnccccciiiiiaaaaalllll RRRRReeeeesssssuuuuullllltttttsssss fffffooooorrrrr FFFFFiiiiirrrrrsssssttttt QQQQQuuuuuaaaaarrrrrttttteeeeerrrrr FFFFFiiiiissssscccccaaaaalllll YYYYYeeeeeaaaaarrrrr 22222000002222266666 (((((AAAAAppppprrrrriiiiilllll 11111,,,,, 22222000002222266666 tttttooooo JJJJJuuuuunnnnneeeee 3333300000,,,,, 22222000002222266666))))) (((((11111))))) CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd OOOOOpppppeeeeerrrrraaaaatttttiiiiinnnnnggggg RRRRReeeeesssssuuuuullllltttttsssss (Percentages indicate year-on-year changes.) Sales revenue Core operating income Operating income Net income Net income attributable to owners of the parent Total comprehensive income Millions of yen % Millions of yen % Millions of yen % Millions of yen % Millions of yen % Millions of yen % Q1 FY2026 578,199 9.9 62,336 125.2 61,041 139.8 51,350 － 40,782 － 91,645 － Q1 FY2025 526,140 (14.0) 27,681 388.2 25,452 121.3 3,873 (88.6) (4,523) － 1,125 (98.4) Basic earnings per share Diluted earnings per share Yen Yen Q1 FY2026 24.70 24.70 Q1 FY2025 (2.76) － Reference: Share of profit (loss) of investments accounted for using the equity method Q1 FY2026: ¥ 12,216 million Q1 FY2025: ¥ (9,826) million Income before taxes Q1 FY2026: ¥ 60,313 million Q1 FY2025: ¥ 5,817 million *Core operating income is a gain and loss concept that reflects recurring earning capacity by deducting gains and losses incurred by non-recurring factors from operating income, which includes the share of profits or losses from investments accounted for using the equity method. *For diluted earnings per share for Q1 FY2025, although there are potential shares, they are not listed because they have an anti-dilutive effect. (((((22222))))) CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd FFFFFiiiiinnnnnaaaaannnnnccccciiiiiaaaaalllll PPPPPooooosssssiiiiitttttiiiiiooooonnnnn Total assets Total equity Equity attributable to owners of the parent Ratio of equity attributable to owners of the parent to total assets As of Millions of yen Millions of yen Millions of yen % June 30, 2026 3,613,506 1,412,442 1,102,863 30.5 March 31, 2026 3,405,041 1,236,673 1,008,644 29.6
Page 2
22222..... DDDDDiiiiivvvvviiiiidddddeeeeennnnndddddsssss Dividends per share 1st quarter end 2nd quarter end 3rd quarter end Year- end Annual Yen Yen Yen Yen Yen FY2025 － 6.00 － 7.50 13.50 FY2026 － FY2026 (Forecast) 8.00 － 8.00 16.00 Note: Revision of dividend forecasts from the latest announcement: None 33333..... CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd FFFFFiiiiinnnnnaaaaannnnnccccciiiiiaaaaalllll FFFFFooooorrrrreeeeecccccaaaaassssstttttsssss fffffooooorrrrr FFFFFiiiiissssscccccaaaaalllll YYYYYeeeeeaaaaarrrrr 22222000002222266666 (((((AAAAAppppprrrrriiiiilllll 11111,,,,, 22222000002222266666 tttttooooo MMMMMaaaaarrrrrccccchhhhh 3333311111,,,,, 22222000002222277777))))) (Percentages indicate year-on-year changes.) Sales revenue Core operating income Operating income Net income attributable to owners of the parent Basic earnings per share Millions of yen % Millions of yen % Millions of yen % Millions of yen % Yen First-half of FY2026 1,170,000 6.8 125,000 15.0 122,000 17.7 70,000 76.3 42.40 Full-year of FY2026 2,360,000 1.4 215,000 3.2 177,000 16.6 70,000 14.9 42.40 Note: Revision of financial forecasts from the latest announcement: None We now announce the consolidated financial forecast for the first-half of FY2026 as above, which was not announced in the "Summary of Consolidated Financial Results for Fiscal Year 2025 (Under IFRS)" disclosed on May 14, 2026. There are no changes to the consolidated financial forecast for FY2026. NNNNNooooottttteeeeesssss::::: (1) Significant changes in the scope of consolidation during the period: None Newly included: － Excluded: － (2) Changes in accounting policies and changes in accounting estimates (i) Changes in accounting policies required by IFRS: Yes (ii) Changes in accounting policies due to other reasons: None (iii) Changes in accounting estimates: None (3) Number of shares issued (common shares) (i) Total number of shares issued at the end of the period (including treasury shares) As of June 30, 2026 1,657,914,399 shares As of March 31, 2026 1,657,914,399 shares (ii) Number of treasury shares at the end of the period As of June 30, 2026 6,503,408 shares As of March 31, 2026 6,500,914 shares (iii) Average number of shares outstanding during the period Three Months ended June 30, 2026 1,651,217,003 shares Three Months ended June 30, 2025 1,636,496,435 shares *Review of the Japanese-language original of the attached quarterly consolidated financial statements by certified public accountants or an audit firm: Yes (voluntary) *Notes regarding the appropriate use of forecasts and other special items: Descriptions regarding forward-looking statements about the future performance of the Company contained in this summary are based on information currently available to the Company and certain assumptions judged reasonable and involve risks and uncertainties. The important factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, general economic conditions in the Company's markets; demand for, and competitive pricing pressure on, the Company's products in the marketplace; rise in prices of raw materials; and fluctuations in foreign exchange rates.
Page 3
1 Attachments 1. Summary of Operating Results for First Quarter Fiscal Year 2026 ................................................... 2 (1) Operating Results ........................................................................................................................... 2 (2) Consolidated Financial Position ...................................................................................................... 3 (3) Consolidated Forecast and Other Forward-Looking Information .................................................... 3 2. Consolidated Financial Statements and Major Notes .......................................................................... 4 (1) Consolidated Statement of Financial Position ................................................................................ 4 (2) Consolidated Statement of Income and Consolidated Statement of Comprehensive Income ....................................................................... 6 (3) Consolidated Statement of Changes in Equity ............................................................................... 8 (4) Consolidated Statement of Cash Flows .........................................................................................10 (5) Notes to Consolidated Financial Statements ..................................................................................11 (Framework of Financial Report) ..................................................................................................11 (Going Concern Assumption) .......................................................................................................11 (Changes in Accounting Policies) .................................................................................................11 (Segment Information) ................................................................................................................. 12
Page 4
2 11111..... SSSSSuuuuummmmmmmmmmaaaaarrrrryyyyy ooooofffff OOOOOpppppeeeeerrrrraaaaatttttiiiiinnnnnggggg RRRRReeeeesssssuuuuullllltttttsssss fffffooooorrrrr FFFFFiiiiirrrrrsssssttttt QQQQQuuuuuaaaaarrrrrttttteeeeerrrrr FFFFFiiiiissssscccccaaaaalllll YYYYYeeeeeaaaaarrrrr 22222000002222266666 (((((11111))))) OOOOOpppppeeeeerrrrraaaaatttttiiiiinnnnnggggg RRRRReeeeesssssuuuuullllltttttsssss The Group's sales revenue for Q1 FY2026 increased by ¥52.1 billion compared to Q1 FY2025, to ¥578.2 billion. In terms of profits and losses, core operating income* was ¥62.3 billion, operating income was ¥61.0 billion, and net income attributable to owners of the parent was ¥40.8 billion. Results in every category of income were higher than in Q1 FY2025. *Core operating income is a gain and loss concept that reflects recurring earning capacity by deducting gains and losses incurred by non-recurring factors from operating income, which includes the share of profits or losses from investments accounted for using the equity method. The financial results by reportable segment for Q1 FY2026 are as follows: AAAAAgggggrrrrrooooo &&&&& LLLLLiiiiifffffeeeee SSSSSooooollllluuuuutttttiiiiiooooonnnnnsssss In addition to sales of crop protection products remaining steady, primarily in Japan, there was also an increase in net income from exports due to the weak yen. Profit margins for methionine (feed additives) also improved. As a result, sales revenue increased by ¥12.1 billion compared to Q1 FY2025, to ¥109.0 billion. Core operating income increased by ¥7.4 billion compared to Q1 FY2025, to ¥9.6 billion. IIIIICCCCCTTTTT &&&&& MMMMMooooobbbbbiiiiillllliiiiitttttyyyyy SSSSSooooollllluuuuutttttiiiiiooooonnnnnsssss Display-related materials were impacted by fundamental structural reforms implemented for the polarizing film business for large-size liquid crystal displays and the resulting decline in capital gains. In semiconductor processing materials, although there was an increase in sales revenue from a growth in demand for high-purity chemicals and photoresists, there was also an increase in fixed costs. Therefore, there was not much of an effect on core operating income. As a result, sales revenue increased by ¥11.2 billion compared to Q1 FY2025, to ¥148.6 billion. Core operating income decreased by ¥5.3 billion compared to Q1 FY2025, to ¥13.0 billion. AAAAAdddddvvvvvaaaaannnnnccccceeeeeddddd MMMMMeeeeedddddiiiiicccccaaaaalllll SSSSSooooollllluuuuutttttiiiiiooooonnnnnsssss In the contract development and manufacturing organization business for advanced small-molecule drug, there was a shift in the sales period. As a result, sales revenue increased by ¥1.4 billion compared to Q1 FY2025, to ¥10.4 billion. On the other hand, the core operating loss from a different product mix of active pharmaceutical ingredients and intermediates further deteriorated by ¥0.9 billion compared to Q1 FY2025, to a loss of ¥1.9 billion. EEEEEsssssssssseeeeennnnntttttiiiiiaaaaalllll &&&&& GGGGGrrrrreeeeeeeeeennnnn MMMMMaaaaattttteeeeerrrrriiiiiaaaaalllllsssss Profit margins improved for Rabigh Refining and Petrochemical Company, an affiliated company accounted for using the equity method. In addition, due to a rise in market prices for synthetic resins and other materials, there was a gain on the difference between the inventory valuation of these materials and their increased market price. As a result, sales revenue increased by ¥4.8 billion compared to Q1 FY2025, to ¥170.2 billion. Core operating income increased by ¥32.7 billion compared to Q1 FY2025, to ¥27.2 billion. SSSSSuuuuummmmmiiiiitttttooooommmmmooooo PPPPPhhhhhaaaaarrrrrmmmmmaaaaa There was an increase in sales revenue from a growth in sales of ORGOVYX ® (therapeutic agent for advanced prostate cancer) and GEMTESA ® (therapeutic agent for overactive bladder) in the US. This offset the decrease in revenue from the partial transfer of the Asian business in the previous fiscal year. As a result, sales revenue increased by ¥21.6 billion compared to Q1 FY2025, to ¥129.0 billion. Core operating income decreased by ¥2.2 billion to ¥18.8 billion compared to Q1 FY2025, due to an increase in R&D expenses from the acceleration of clinical trials in the area of oncology and advancements in the area of neuropsychiatry. Sales revenue and core operating income differ between this segment and the results reported by Sumitomo Pharma Co., Ltd., a consolidated subsidiary of Sumitomo Chemical Co., Ltd., due to the Group's contract and manufacturing business for regenerative medicine and cell therapy products not being included in this segment and because of the Group's consolidated account reporting. OOOOOttttthhhhheeeeerrrrrsssss In addition to the above five segments, the Group supplies electric power and steam, and also provides transportation and warehousing. Sales revenue increased by ¥1.0 billion compared to Q1 FY2025, to ¥11.0 billion. Core operating income increased by ¥1.3 billion compared to Q1 FY2025, to ¥3.1 billion.
Page 5
3 (((((22222))))) CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd FFFFFiiiiinnnnnaaaaannnnnccccciiiiiaaaaalllll PPPPPooooosssssiiiiitttttiiiiiooooonnnnn As of the end of Q1 FY2026, total assets increased by ¥208.5 billion compared to the end of FY2025, to ¥3,613.5 billion. Trade and other receivables as well as inventories increased due to higher raw material prices. Total liabilities increased by ¥32.7 billion compared to the end of FY2025, to ¥2,201.1 billion. Interest-bearing liabilities decreased by ¥19.3 billion compared to the end of FY2025, to ¥1,132.2 billion. Total equity (including non-controlling interests) increased by ¥175.8 billion compared to the end of FY2025, to ¥1,412.4 billion, because of increases in non-controlling interests and capital surplus mainly due to capital increase through a public offering conducted by Sumitomo Pharma Co., Ltd. during Q1 FY2026. The ratio of equity attributable to the owners of the parent to total assets increased by 0.9 percentage points compared to the end of FY2025, to 30.5%. (((((33333))))) CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd FFFFFooooorrrrreeeeecccccaaaaasssssttttt aaaaannnnnddddd OOOOOttttthhhhheeeeerrrrr FFFFFooooorrrrrwwwwwaaaaarrrrrddddd-----LLLLLooooooooookkkkkiiiiinnnnnggggg IIIIInnnnnfffffooooorrrrrmmmmmaaaaatttttiiiiiooooonnnnn Based on recent performance trends, the Company announces its previously undisclosed consolidated financial forecast for the first half of FY2026, as detailed below, assuming an average exchange rate of 157.00 yen/US$ and a naphtha price of 104,000 yen/KL. The forecast for FY2026 is currently under review and the revised forecast will be explained when the consolidated financial results for the first half of FY2026 are announced. CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd FFFFFiiiiinnnnnaaaaannnnnccccciiiiiaaaaalllll FFFFFooooorrrrreeeeecccccaaaaasssssttttt fffffooooorrrrr ttttthhhhheeeee FFFFFiiiiirrrrrsssssttttt HHHHHaaaaalllllfffff ooooofffff FFFFFYYYYY22222000002222266666 (((((AAAAAppppprrrrriiiiilllll 11111,,,,, 22222000002222266666 ––––– SSSSSeeeeepppppttttteeeeemmmmmbbbbbeeeeerrrrr 3333300000,,,,, 22222000002222266666))))) (Millions of yen) Sales Revenue Core Operating Income Operating Income Net Income Attributable to Owners of the Parent Earnings per Share (yen) Previous forecast (A) TBD TBD TBD TBD TBD Revised forecast (B) 1,170,000 125,000 122,000 70,000 42.40 Variance in amount (B-A) - - - - Variance in percentage (%) - - - - Results for the first half of FY2025 1,095,394 108,716 103,685 39,699 24.26 (Supplemental information) CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd FFFFFiiiiinnnnnaaaaannnnnccccciiiiiaaaaalllll FFFFFooooorrrrreeeeecccccaaaaasssssttttt bbbbbyyyyy SSSSSeeeeegggggmmmmmeeeeennnnnttttt fffffooooorrrrr ttttthhhhheeeee FFFFFiiiiirrrrrsssssttttt HHHHHaaaaalllllfffff ooooofffff FFFFFYYYYY22222000002222266666 (Millions of yen) Current forecast Results for the first half of FY2025 Agro & Life Solutions Sales revenue 260,000 212,971 Core operating income 29,000 11,227 ICT & Mobility Solutions Sales revenue 310,000 283,482 Core operating income 28,000 33,109 Advanced Medical Solutions Sales revenue 28,000 21,142 Core operating income 0 (1,380) Essential & Green Materials Sales revenue 300,000 329,144 Core operating income 42,000 (18,610) Sumitomo Pharma Sales revenue 250,000 226,071 Core operating income 32,000 97,320 Others & Adjustments Sales revenue 22,000 22,584 Core operating income (6,000) (12,950) Total Sales revenue 1,170,000 1,095,394 Core operating income 125,000 108,716
Page 6
4 22222..... CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd FFFFFiiiiinnnnnaaaaannnnnccccciiiiiaaaaalllll SSSSStttttaaaaattttteeeeemmmmmeeeeennnnntttttsssss aaaaannnnnddddd MMMMMaaaaajjjjjooooorrrrr NNNNNooooottttteeeeesssss (((((11111))))) CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd SSSSStttttaaaaattttteeeeemmmmmeeeeennnnnttttt ooooofffff FFFFFiiiiinnnnnaaaaannnnnccccciiiiiaaaaalllll PPPPPooooosssssiiiiitttttiiiiiooooonnnnn Millions of yen As of June 30, 2026 As of March 31, 2026 AAAAAsssssssssseeeeetttttsssss Current assets: Cash and cash equivalents ¥ 223,197 ¥ 208,589 Trade and other receivables 644,529 608,670 Other financial assets 63,561 47,551 Inventories 643,620 595,471 Other current assets 64,519 47,429 Subtotal 1,639,426 1,507,710 Assets held for sale 19,633 － Total current assets 1,659,059 1,507,710 Non-current assets: Property, plant and equipment 777,557 770,688 Goodwill 280,323 275,711 Intangible assets 222,213 225,334 Investments accounted for using the equity method 220,357 203,862 Other financial assets 330,041 301,222 Retirement benefit assets 53,294 52,222 Deferred tax assets 41,035 39,227 Other non-current assets 29,627 29,065 Total non-current assets 1,954,447 1,897,331 Total assets ¥ 3,613,506 ¥ 3,405,041
Page 7
5 Millions of yen As of June 30, 2026 As of March 31, 2026 LLLLLiiiiiaaaaabbbbbiiiiillllliiiiitttttiiiiieeeeesssss aaaaannnnnddddd eeeeeqqqqquuuuuiiiiitttttyyyyy LLLLLiiiiiaaaaabbbbbiiiiillllliiiiitttttiiiiieeeeesssss Current liabilities: Bonds and borrowings ¥ 288,550 ¥ 241,422 Trade and other payables 550,097 464,422 Other financial liabilities 52,565 63,737 Income taxes payable 12,681 7,022 Provisions 113,366 110,408 Other current liabilities 85,830 114,335 Subtotal 1,103,089 1,001,346 Liabilities directly associated with assets held for sale 755 － Total current liabilities 1,103,844 1,001,346 Non-current liabilities: Bonds and borrowings 843,618 910,033 Other financial liabilities 86,496 87,885 Retirement benefit liabilities 22,640 22,084 Provisions 24,728 26,383 Deferred tax liabilities 84,453 78,321 Other non-current liabilities 35,285 42,316 Total non-current liabilities 1,097,220 1,167,022 Total liabilities 2,201,064 2,168,368 EEEEEqqqqquuuuuiiiiitttttyyyyy Share capital 90,179 90,179 Capital surplus 35,686 1,966 Retained earnings 684,719 655,384 Treasury shares (2,651) (2,650) Other components of equity 294,930 263,765 Equity attributable to owners of the parent 1,102,863 1,008,644 Non-controlling interests 309,579 228,029 Total equity 1,412,442 1,236,673 Total liabilities and equity ¥ 3,613,506 ¥ 3,405,041
Page 8
6 (((((22222))))) CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd SSSSStttttaaaaattttteeeeemmmmmeeeeennnnnttttt ooooofffff IIIIInnnnncccccooooommmmmeeeee aaaaannnnnddddd CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd SSSSStttttaaaaattttteeeeemmmmmeeeeennnnnttttt ooooofffff CCCCCooooommmmmppppprrrrreeeeehhhhheeeeennnnnsssssiiiiivvvvveeeee IIIIInnnnncccccooooommmmmeeeee CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd SSSSStttttaaaaattttteeeeemmmmmeeeeennnnnttttt ooooofffff IIIIInnnnncccccooooommmmmeeeee First Quarter ended June 30, 2026 and 2025 Millions of yen Q1 FY2026 Q1 FY2025 Sales revenue ¥ 578,199 ¥ 526,140 Cost of sales (383,984) (362,436) Gross profit 194,215 163,704 Selling, general and administrative expenses (145,570) (133,621) Other operating income 3,547 10,347 Other operating expenses (3,367) (5,152) Share of profit (loss) of investments accounted for using the equity method 12,216 (9,826) Operating income 61,041 25,452 Finance income 12,551 6,681 Finance expenses (13,279) (26,316) Income before taxes 60,313 5,817 Income tax expenses (8,963) (1,944) Net income 51,350 3,873 Net income (loss) attributable to: Owners of the parent 40,782 (4,523) Non-controlling interests 10,568 8,396 Net income ¥ 51,350 ¥ 3,873 Yen Q1 FY2026 Q1 FY2025 Earnings per share: Basic earnings (loss) per share 24.70 (2.76) Diluted earnings per share 24.70 －
Page 9
7 CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd SSSSStttttaaaaattttteeeeemmmmmeeeeennnnnttttt ooooofffff CCCCCooooommmmmppppprrrrreeeeehhhhheeeeennnnnsssssiiiiivvvvveeeee IIIIInnnnncccccooooommmmmeeeee First Quarter ended June 30, 2026 and 2025 Millions of yen Q1 FY2026 Q1 FY2025 Net income ¥ 51,350 ¥ 3,873 Other comprehensive income: Items that will not be reclassified to profit or loss Remeasurements of financial assets (equity instruments) measured at fair value through other comprehensive income 21,435 5,464 Remeasurements of defined benefit plans (16) 227 Share of other comprehensive income of investments accounted for using the equity method 3,121 203 Total items that will not be reclassified to profit or loss 24,540 5,894 Items that may be subsequently reclassified to profit or loss Remeasurements of financial assets (debt instruments) measured at fair value through other comprehensive income － 23 Cash flow hedges 275 (354) Exchange differences on conversion of foreign operations 13,213 149 Share of other comprehensive income of investments accounted for using the equity method 2,267 (8,460) Total items that may be subsequently reclassified to profit or loss 15,755 (8,642) Other comprehensive income, net of taxes 40,295 (2,748) Total comprehensive income 91,645 1,125 Total comprehensive income attributable to: Owners of the parent 78,938 (5,105) Non-controlling interests 12,707 6,230 Total comprehensive income ¥ 91,645 ¥ 1,125
Page 10
8 (((((33333))))) CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd SSSSStttttaaaaattttteeeeemmmmmeeeeennnnnttttt ooooofffff CCCCChhhhhaaaaannnnngggggeeeeesssss iiiiinnnnn EEEEEqqqqquuuuuiiiiitttttyyyyy First Quarter ended June 30, 2026 Millions of yen Equity attributable to owners of the parent Other components of equity Share capital Capital surplus Retained earnings Treasury shares Remeasurements of financial assets measured at fair value through other comprehensive income Remeasurements of defined benefit plans Balance as of April 1, 2026 ¥ 90,179 ¥ 1,966 ¥ 655,384 ¥ (2,650) ¥ 43,393 ¥ － Net income (loss) － － 40,782 － － － Other comprehensive income － － － － 23,639 508 Total comprehensive income － － 40,782 － 23,639 508 Purchase of treasury shares － － － (1) － － Disposal of treasury shares － (0) － 0 － － Dividends － － (12,386) － － － Changes resulting from loss of control of subsidiaries － － － － － － Changes in interest due to transactions with non-controlling interests － 33,769 － － 51 － Transfer from other components of equity to retained earnings － － 939 － (431) (508) Others, net － (49) － － － － Transfer to other comprehensive income associated with assets held for sale － － － － － － Total transactions with owners － 33,720 (11,447) (1) (380) (508) Balance as of June 30, 2026 ¥ 90,179 ¥ 35,686 ¥ 684,719 ¥ (2,651) ¥ 66,652 ¥ － Equity attributable to owners of the parent Non-controlling interests Total equity Other components of equity Other comprehensive income associated with assets held for sale Equity attributable to owners of the parent Cash flow hedges Exchange differences on conversion of foreign operations Total Balance as of April 1, 2026 ¥ (214) ¥ 220,586 ¥ 263,765 ¥ － ¥1,008,644 ¥ 228,029 ¥1,236,673 Net income (loss) － － － － 40,782 10,568 51,350 Other comprehensive income 267 13,742 38,156 － 38,156 2,139 40,295 Total comprehensive income 267 13,742 38,156 － 78,938 12,707 91,645 Purchase of treasury shares － － － － (1) － (1) Disposal of treasury shares － － － － 0 － 0 Dividends － － － － (12,386) (614) (13,000) Changes resulting from loss of control of subsidiaries － － － － － － － Changes in interest due to transactions with non-controlling interests － (6,103) (6,052) － 27,717 69,457 97,174 Transfer from other components of equity to retained earnings － － (939) － － － － Others, net － － － － (49) － (49) Transfer to other comprehensive income associated with assets held for sale － － － － － － － Total transactions with owners － (6,103) (6,991) － 15,281 68,843 84,124 Balance as of June 30, 2026 ¥ 53 ¥ 228,225 ¥ 294,930 ¥ － ¥1,102,863 ¥ 309,579 ¥1,412,442
Page 11
9 First Quarter ended June 30, 2025 Millions of yen Equity attributable to owners of the parent Other components of equity Share capital Capital surplus Retained earnings Treasury shares Remeasurements of financial assets measured at fair value through other comprehensive income Remeasurements of defined benefit plans Balance as of April 1, 2025 ¥ 90,059 ¥ － ¥ 640,611 ¥ (8,361) ¥ 1,186 ¥ － Net income (loss) － － (4,523) － － － Other comprehensive income － － － － 5,736 224 Total comprehensive income － － (4,523) － 5,736 224 Purchase of treasury shares － － － (1) － － Disposal of treasury shares － － (0) 0 － － Dividends － － (9,820) － － － Changes resulting from loss of control of subsidiaries － － 1,832 － (1,611) (221) Changes in interest due to transactions with non-controlling interests － － － － － － Transfer from other components of equity to retained earnings － － (34) － 37 (3) Others, net － － － － － － Transfer to other comprehensive income associated with assets held for sale － － － － － － Total transactions with owners － － (8,022) (1) (1,574) (224) Balance as of June 30, 2025 ¥ 90,059 ¥ － ¥ 628,066 ¥ (8,361) ¥ 5,348 ¥ － Equity attributable to owners of the parent Non-controlling interests Total equity Other components of equity Other comprehensive income associated with assets held for sale Equity attributable to owners of the parent Cash flow hedges Exchange differences on conversion of foreign operations Total Balance as of April 1, 2025 ¥ 87 ¥ 173,598 ¥ 174,871 ¥ 3,610 ¥ 900,790 ¥ 173,625 ¥1,074,415 Net income (loss) － － － － (4,523) 8,396 3,873 Other comprehensive income (364) (2,890) 2,706 (3,288) (582) (2,166) (2,748) Total comprehensive income (364) (2,890) 2,706 (3,288) (5,105) 6,230 1,125 Purchase of treasury shares － － － － (1) － (1) Disposal of treasury shares － － － － 0 － 0 Dividends － － － － (9,820) (1,154) (10,974) Changes resulting from loss of control of subsidiaries － － (1,832) － － (3,176) (3,176) Changes in interest due to transactions with non-controlling interests － － － － － － － Transfer from other components of equity to retained earnings － － 34 － － － － Others, net － － － － － － － Transfer to other comprehensive income associated with assets held for sale － (2,480) (2,480) 2,480 － － － Total transactions with owners － (2,480) (4,278) 2,480 (9,821) (4,330) (14,151) Balance as of June 30, 2025 ¥ (277) ¥ 168,228 ¥ 173,299 ¥ 2,802 ¥ 885,865 ¥ 175,525 ¥1,061,390
Page 12
10 (((((44444))))) CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd SSSSStttttaaaaattttteeeeemmmmmeeeeennnnnttttt ooooofffff CCCCCaaaaassssshhhhh FFFFFlllllooooowwwwwsssss First Quarter ended June 30, 2026 and 2025 Millions of yen Q1 FY2026 Q1 FY2025 Cash flows from operating activities: Income before taxes ¥ 60,313 ¥ 5,817 Depreciation and amortization 29,117 29,720 Share of (profit) loss of investments accounted for using the equity method (12,216) 9,826 Interest and dividend income (6,934) (4,127) Interest expenses 9,558 7,369 Restructuring costs 1,070 2,733 (Increase) decrease in trade receivables 25,916 61,306 (Increase) decrease in inventories (62,588) (37,499) Increase (decrease) in trade payables 92,555 8,516 Increase (decrease) in unearned revenue (4,568) (1,567) Increase (decrease) in provisions 5,003 1,014 Others, net (117,010) (49,539) Subtotal 20,216 33,569 Interest and dividends received 9,330 6,473 Interest paid (7,961) (5,770) Income taxes paid (5,772) (9,522) Restructuring costs paid (10,848) (752) Net cash provided by (used in) operating activities 4,965 23,998 Cash flows from investing activities: Net (increase) decrease in time deposits (12,307) (3,264) Net (increase) decrease in securities (3,106) (11,991) Purchase of property, plant and equipment, and intangible assets (35,907) (37,860) Proceeds from sales of property, plant and equipment, and intangible assets 466 1,127 Proceeds from sales of subsidiaries － 12,323 Payments for sales of subsidiaries － (6,508) Purchase of other financial assets (1,144) (1,141) Proceeds from sales and redemption of other financial assets 2,786 141 Others, net (20) 1,227 Net cash provided by (used in) investing activities (49,232) (45,946) Cash flows from financing activities: Net increase (decrease) in short-term borrowings 10,605 16,495 Net increase (decrease) in commercial paper 36,000 (24,000) Repayments of long-term borrowings (69,623) (25,705) Repayments of lease liabilities (4,194) (4,236) Cash dividends paid (12,394) (9,828) Cash dividends paid to non-controlling interests (615) (1,155) Capital contribution from non-controlling interests 96,875 － Others, net (1,085) (810) Net cash provided by (used in) financing activities 55,569 (49,239) Effect of exchange rate changes on cash and cash equivalents 3,306 (880) Increase (decrease) in cash and cash equivalents 14,608 (72,067) Cash and cash equivalents at the beginning of the year 208,589 209,838 Net increase (decrease) in cash and cash equivalents resulting from transfer to assets held for sale － 4,790 Cash and cash equivalents at the end of the period ¥ 223,197 ¥ 142,561
Page 13
11 (((((55555))))) NNNNNooooottttteeeeesssss tttttooooo CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd FFFFFiiiiinnnnnaaaaannnnnccccciiiiiaaaaalllll SSSSStttttaaaaattttteeeeemmmmmeeeeennnnntttttsssss FFFFFrrrrraaaaammmmmeeeeewwwwwooooorrrrrkkkkk ooooofffff FFFFFiiiiinnnnnaaaaannnnnccccciiiiiaaaaalllll RRRRReeeeepppppooooorrrrrttttt The Group's quarterly consolidated financial statements are prepared in accordance with Article 5, Paragraph 2 of the Tokyo Stock Exchange, Inc.'s Standards for the Preparation of Quarterly Financial Statements, applying the omitted disclosures as set forth in Article 5, Paragraph 5 of the Standards for the Preparation of Quarterly Financial Statements. GGGGGoooooiiiiinnnnnggggg CCCCCooooonnnnnccccceeeeerrrrrnnnnn AAAAAssssssssssuuuuummmmmppppptttttiiiiiooooonnnnn Not applicable. CCCCChhhhhaaaaannnnngggggeeeeesssss iiiiinnnnn AAAAAccccccccccooooouuuuunnnnntttttiiiiinnnnnggggg PPPPPooooollllliiiiiccccciiiiieeeeesssss The material accounting policies adopted for the Group's quarterly consolidated financial statements are the same as those for the consolidated financial statements for the fiscal year ended March 31, 2026, with the exception of the items described below. The items described below are the accounting standards applied by the Group starting from fiscal year ended March 31, 2027, in compliance with each transitional provision. The effect of the application of the following standards on the Group’s quarterly consolidated financial statements is immaterial. Standards Name of standards Description of new standards and amendments IFRS 7 IFRS 9 Financial Instruments: Disclosures Financial Instruments ・Clarifying the classification of financial assets (clarifying elements for assessing whether the contractual cash flows meet the solely payments of principal and interest (SPPI) criterion) ・Clarifying the date of derecognition of financial liabilities settled through electronic cash transfer systems ・Amendments to the disclosures for investments in equity instruments designated to be measured at fair value through other comprehensive income (FVTOCI) and financial instruments with contingent features that can change cash flows
Page 14
12 SSSSSeeeeegggggmmmmmeeeeennnnnttttt IIIIInnnnnfffffooooorrrrrmmmmmaaaaatttttiiiiiooooonnnnn 11111..... RRRRReeeeepppppooooorrrrrtttttaaaaabbbbbllllleeeee SSSSSeeeeegggggmmmmmeeeeennnnntttttsssss The reportable segments of the Group refer to business units for which separate financial information is available and that are reviewed regularly at the Board of Directors meeting in order to determine the allocation of management resources and evaluate the business performance of each business unit. The Group divides its operations into business sectors identified by products and services, which manage manufacturing, sales, and research in an integrated manner. Each business sector is responsible for developing comprehensive domestic and overseas strategies with respect to its products and services, and operates its business activities. Principally in accordance with the business sectors, the Group consists of the five reportable segments based on its products and services: "Agro & Life Solutions", "ICT & Mobility Solutions", "Advanced Medical Solutions", "Essential & Green Materials", and "Sumitomo Pharma". The major products and services of each reportable segment are as follows: Reportable Segment Major Products and Services Agro & Life Solutions Crop protection chemicals, fertilizers, agricultural materials, household insecticides, products for control of infectious diseases, feed additives, etc. ICT & Mobility Solutions Optical products, semiconductor processing materials, compound semiconductor materials, touch screen sensor panels, high-purity aluminum and alumina, specialty chemicals, additives, engineering plastics, battery materials, etc. Advanced Medical Solutions Contract development and manufacturing organization business for advanced small-molecule drug, oligonucleotides, and regenerative medicine and cell therapy products, etc. Essential & Green Materials Synthetic resins, raw materials for synthetic fibers, various industrial chemicals, methyl methacrylate products, synthetic resin processed products, industrial alumina, synthetic rubber, etc. Sumitomo Pharma Small molecule pharmaceuticals 22222..... RRRRReeeeepppppooooorrrrrtttttaaaaabbbbbllllleeeee SSSSSeeeeegggggmmmmmeeeeennnnnttttt IIIIInnnnnfffffooooorrrrrmmmmmaaaaatttttiiiiiooooonnnnn The accounting methods for each reportable segment are, in principle, identical to those used in the consolidated financial statements. The segment profit or loss is core operating income, which is calculated from operating income after excluding effects from non-recurring factors. Inter-segment sales revenue is based on market prices.
Page 15
13 First Quarter Fiscal Year 2026 Millions of yen Agro & Life Solutions ICT & Mobility Solutions Advanced Medical Solutions Essential & Green Materials Sumitomo Pharma Total Others (Note 1) Adjustments (Note 2) Consoli- dated Sales revenue: Sales revenues from external customers ¥ 108,986 ¥ 148,573 ¥ 10,447 ¥ 170,192 ¥ 128,996 ¥ 567,194 ¥ 11,005 ¥ － ¥ 578,199 Inter-segment sales revenues 266 1,252 2,592 1,673 499 6,282 11,387 (17,669) － Total sales revenue 109,252 149,825 13,039 171,865 129,495 573,476 22,392 (17,669) 578,199 Segment profit (loss) : core operating income (loss) ¥ 9,631 ¥ 13,034 ¥ (1,938) ¥ 27,224 ¥ 18,846 ¥ 66,797 ¥ 3,060 ¥ (7,521) ¥ 62,336 Note 1: "Others" represents businesses such as supplying electrical power and steam, and providing transport and warehousing, which are not included in reportable segments. Note 2: ¥(7,521) million for segment profit (loss) in "Adjustments" includes inter-segment elimination of ¥515 million and corporate expenses of ¥(8,036) million unallocated to each reportable segment. Corporate expenses are mainly research and development expenses for company-wide research, which are not treated as attributable to specific reportable segments. First Quarter Fiscal Year 2025 Millions of yen Agro & Life Solutions ICT & Mobility Solutions Advanced Medical Solutions Essential & Green Materials Sumitomo Pharma Total Others (Note 1) Adjustments (Note 2) Consoli- dated Sales revenue: Sales revenues from external customers ¥ 96,915 ¥ 137,412 ¥ 9,086 ¥ 165,379 ¥ 107,362 ¥ 516,154 ¥ 9,986 ¥ － ¥ 526,140 Inter-segment sales revenues 241 1,007 3,700 1,217 640 6,805 12,941 (19,746) － Total sales revenue 97,156 138,419 12,786 166,596 108,002 522,959 22,927 (19,746) 526,140 Segment profit (loss) : core operating income (loss) ¥ 2,219 ¥ 18,370 ¥ (1,024) ¥ (5,463) ¥ 21,003 ¥ 35,105 ¥ 1,751 ¥ (9,175) ¥ 27,681 Note 1: "Others" represented businesses such as supplying electrical power and steam, and providing transport and warehousing, which were not included in reportable segments. Note 2: ¥(9,175) million for segment profit (loss) in "Adjustments" included inter-segment elimination of ¥154 million and corporate expenses of ¥(9,329) million unallocated to each reportable segment. Corporate expenses were mainly research and development expenses for company-wide research, which were not treated as attributable to specific reportable segments.
Page 16
14 Adjustments to income before taxes from core operating income were as follows: Millions of yen Q1 FY2026 Q1 FY2025 Core operating income ¥ 62,336 ¥ 27,681 Restructuring costs (1,070) (2,733) Others, net (225) 504 Operating income 61,041 25,452 Finance income 12,551 6,681 Finance expenses (13,279) (26,316) Income before taxes ¥ 60,313 ¥ 5,817
Page 17
KKKKKeeeeeyyyyy FFFFFiiiiiggggguuuuurrrrreeeeesssss ooooofffff CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd FFFFFiiiiinnnnnaaaaannnnnccccciiiiiaaaaalllll RRRRReeeeesssssuuuuullllltttttsssss fffffooooorrrrr 11111sssssttttt QQQQQuuuuuaaaaarrrrrttttteeeeerrrrr FFFFFYYYYY22222000002222266666 AAAAAuuuuuggggguuuuusssssttttt 44444,,,,, 22222000002222266666 SSSSSuuuuummmmmiiiiitttttooooommmmmooooo CCCCChhhhheeeeemmmmmiiiiicccccaaaaalllll CCCCCooooo.....,,,,, LLLLLtttttddddd..... 11111..... FFFFFiiiiinnnnnaaaaannnnnccccciiiiiaaaaalllll SSSSSuuuuummmmmmmmmmaaaaarrrrryyyyy (((((IIIIIFFFFFRRRRRSSSSS))))) (Billions of yen) QQQQQ11111 FFFFFYYYYY22222000002222266666 QQQQQ11111 FFFFFYYYYY22222000002222255555 VVVVVaaaaarrrrriiiiiaaaaannnnnccccceeeee FFFFFYYYYY22222000002222266666 (((((FFFFFooooorrrrreeeeecccccaaaaasssssttttt aaaaannnnnnnnnnooooouuuuunnnnnccccceeeeeddddd iiiiinnnnn MMMMMaaaaayyyyy))))) FFFFFYYYYY22222000002222255555 Sales revenue 555557777788888.....22222 526.1 52.1 2,360.0 2,328.5 Core operating income 6666622222.....33333 27.7 34.7 215.0 208.4 Operating income 6666611111.....00000 25.5 35.6 177.0 151.7 Net income (loss) attributable to owners of the parent 4444400000.....88888 (4.5) 45.3 70.0 60.9 Basic earnings (loss) per share ¥¥¥¥¥ 2222244444.....7777700000 ¥ (2.76) ¥ 27.46 ¥ 42.40 ¥ 37.16 Return on equity 33333.....99999%%%%% (0.5)% 4.4% 6.8% 6.4% Exchange rate (yen/$) 111115555599999.....5555577777 144.59 － 155.00 150.67 Naphtha price (yen/kl) 111111111188888,,,,,555550000000000 66,300 － 92,000 65,200 *Core operating income is a gain and loss concept that reflects recurring earning capacity by deducting gains and losses incurred by non-recurring factors from operating income, which includes the share of profits or losses from investments accounted for using the equity method. 22222..... SSSSSaaaaallllleeeeesssss RRRRReeeeevvvvveeeeennnnnuuuuueeeee ///// CCCCCooooorrrrreeeee OOOOOpppppeeeeerrrrraaaaatttttiiiiinnnnnggggg IIIIInnnnncccccooooommmmmeeeee bbbbbyyyyy RRRRReeeeepppppooooorrrrrtttttiiiiinnnnnggggg SSSSSeeeeegggggmmmmmeeeeennnnnttttt (((((IIIIIFFFFFRRRRRSSSSS))))) (Billions of yen) QQQQQ11111 FFFFFYYYYY22222000002222266666 QQQQQ11111 FFFFFYYYYY22222000002222255555 VVVVVaaaaarrrrriiiiiaaaaannnnnccccceeeee FFFFFYYYYY22222000002222266666 (((((FFFFFooooorrrrreeeeecccccaaaaasssssttttt aaaaannnnnnnnnnooooouuuuunnnnnccccceeeeeddddd iiiiinnnnn MMMMMaaaaayyyyy))))) FFFFFYYYYY22222000002222255555 Agro & Life Solutions Sales revenue 111110000099999.....00000 96.9 12.1 560.0 519.3 Core operating income 99999.....66666 2.2 7.4 65.0 56.3 ICT & Mobility Solutions Sales revenue 111114444488888.....66666 137.4 11.2 590.0 574.2 Core operating income 1111133333.....00000 18.4 (5.3) 55.0 53.0 Advanced Medical Solutions Sales revenue 1111100000.....44444 9.1 1.4 60.0 58.6 Core operating income (((((11111.....99999))))) (1.0) (0.9) 3.0 2.8 Essential & Green Materials Sales revenue 111117777700000.....22222 165.4 4.8 560.0 678.8 Core operating income 2222277777.....22222 (5.5) 32.7 20.0 14.4 Sumitomo Pharma Sales revenue 111112222299999.....00000 107.4 21.6 540.0 451.9 Core operating income 1111188888.....88888 21.0 (2.2) 94.0 108.4 Others Sales revenue 1111111111.....00000 10.0 1.0 50.0 45.8 Core operating income 33333.....11111 1.8 1.3 4.0 4.4 Adjustments Sales revenue －－－－－ － － － － Core operating income (((((77777.....55555))))) (9.2) 1.7 (26.0) (31.1) Total Sales revenue 555557777788888.....22222 526.1 52.1 2,360.0 2,328.5 Core operating income 6666622222.....33333 27.7 34.7 215.0 208.4
Page 18
33333..... SSSSSuuuuummmmmmmmmmaaaaarrrrryyyyy ooooofffff CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd SSSSStttttaaaaattttteeeeemmmmmeeeeennnnnttttt ooooofffff IIIIInnnnncccccooooommmmmeeeee (((((IIIIIFFFFFRRRRRSSSSS))))) (Billions of yen) QQQQQ11111 FFFFFYYYYY22222000002222266666 QQQQQ11111 FFFFFYYYYY22222000002222255555 VVVVVaaaaarrrrriiiiiaaaaannnnnccccceeeee VVVVVaaaaarrrrriiiiiaaaaannnnnccccceeeee RRRRRaaaaatttttiiiiiooooo Sales revenue 555557777788888.....22222 526.1 52.1 9.9% Core operating income 6666622222.....33333 27.7 34.7 125.2% of which equity-method investments 1111122222.....22222 (9.8) 22.0 － Total non-recurring items (breakdown below) (((((11111.....33333))))) (2.2) 0.9 － Restructuring costs (((((11111.....11111))))) (2.7) 1.7 － Others (((((00000.....22222))))) 0.5 (0.7) － Operating income 6666611111.....00000 25.5 35.6 139.8% Finance income/expenses (breakdown below) (((((00000.....77777))))) (19.6) 18.9 － Gain (loss) on foreign currency transactions including gain (loss) on derivatives 11111.....66666 (16.4) (18.0) － Others (((((22222.....33333))))) (3.3) (0.9) － Income before taxes 6666600000.....33333 5.8 54.5 936.8% Income tax expenses (((((99999.....00000))))) (1.9) (7.0) － Net income 5555511111.....44444 3.9 47.5 － Net (income) attributable to non-controlling interests (((((1111100000.....66666))))) (8.4) (2.2) － Net income (loss) attributable to owners of the parent 4444400000.....88888 (4.5) 45.3 － ROE 33333.....99999%%%%% (0.5)% Exchange rate (yen/$) 111115555599999.....5555577777 144.59 Naphtha price (yen/kl) 111111111188888,,,,,555550000000000 66,300 Overseas sales revenue ratio 6666677777.....77777%%%%% 68.5% 44444..... SSSSSuuuuummmmmmmmmmaaaaarrrrryyyyy ooooofffff CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd SSSSStttttaaaaattttteeeeemmmmmeeeeennnnnttttt ooooofffff FFFFFiiiiinnnnnaaaaannnnnccccciiiiiaaaaalllll PPPPPooooosssssiiiiitttttiiiiiooooonnnnn (((((IIIIIFFFFFRRRRRSSSSS))))) (Billions of yen) 3333300000-----JJJJJuuuuunnnnneeeee-----2222266666 3333311111-----MMMMMaaaaarrrrr-----2222266666 VVVVVaaaaarrrrriiiiiaaaaannnnnccccceeeee 3333300000-----JJJJJuuuuunnnnneeeee-----2222266666 3333311111-----MMMMMaaaaarrrrr-----2222266666 VVVVVaaaaarrrrriiiiiaaaaannnnnccccceeeee Current Assets 11111,,,,,666665555599999.....11111 1,507.7 151.3 Liabilities 22222,,,,,222220000011111.....11111 2,168.4 32.7 Cash and cash equivalents 222222222233333.....22222 208.6 14.6 Trade and other payables 555555555500000.....11111 464.4 85.7 Trade and other receivables 666664444444444.....55555 608.7 35.9 Interest-bearing liabilities 11111,,,,,111113333322222.....22222 1,151.5 (19.3) Inventories 666664444433333.....66666 595.5 48.1 Others 555551111188888.....88888 552.5 (33.7) Others 111114444477777.....77777 95.0 52.7 Equity 11111,,,,,444441111122222.....44444 1,236.7 175.8 Non-current assets 11111,,,,,999995555544444.....44444 1,897.3 57.1 Shareholders' equity 888880000077777.....99999 744.9 63.1 Property, plant and equipment 777777777777777.....66666 770.7 6.9 Other components of equity 222229999944444.....99999 263.8 31.2 Goodwill and intangible assets 555550000022222.....55555 501.0 1.5 Non-controlling interests 333330000099999.....66666 228.0 81.6 Others 666667777744444.....44444 625.6 48.8 Total 33333,,,,,666661111133333.....55555 3,405.0 208.5 Total 33333,,,,,666661111133333.....55555 3,405.0 208.5 Ratio of equity attributable to owners of the parent to total assets 3333300000.....55555%%%%% 29.6% 0.9% D/E ratio (times) 00000.....8888800000 0.93 (0.13)
Page 19
55555..... SSSSSuuuuummmmmmmmmmaaaaarrrrryyyyy ooooofffff CCCCCooooonnnnnsssssooooollllliiiiidddddaaaaattttteeeeeddddd SSSSStttttaaaaattttteeeeemmmmmeeeeennnnnttttt ooooofffff CCCCCaaaaassssshhhhh FFFFFlllllooooowwwwwsssss (((((IIIIIFFFFFRRRRRSSSSS))))) (Billions of yen) QQQQQ11111 FFFFFYYYYY22222000002222266666 QQQQQ11111 FFFFFYYYYY22222000002222255555 VVVVVaaaaarrrrriiiiiaaaaannnnnccccceeeee FFFFFYYYYY22222000002222255555 Cash flows from operating activities 55555.....00000 24.0 (19.0) 234.8 Cash flows from investing activities (((((4444499999.....22222))))) (45.9) (3.3) (74.8) Free cash flows (((((4444444444.....33333))))) (21.9) (22.3) 159.9 Cash flows from financing activities 5555555555.....66666 (49.2) 104.8 (199.1) Others 33333.....33333 (0.9) 4.2 15.7 Increase (decrease) in cash and cash equivalents 1111144444.....66666 (72.1) 86.7 (23.5) Cash and cash equivalents at the end of the period 222222222233333.....22222 142.6 80.6 208.6